Morria Reports Safety Results of Phase I Allergy Drug
Posted on: Tuesday, 19 February 2008, 12:00 CST
Morria Biopharmaceuticals has reported the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis or AR.
MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed, with blood analysis and pharmacokinetic data further indicating safety. Morria plans to initiate a Phase II efficacy clinical study with 175 patients, who will be treated for six days prior to allergen challenge.
Yuval Cohen, president of Morria, said: "We are entirely satisfied with these results. They mark an important milestone in our clinical development plan, which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar AR market."
Source: Datamonitor
Related Articles
- Morria Initiates Phase II Allergic Rhinitis Trial
- Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
- Morria Biopharma Reports Safety Results From Phase I Rhinitis Study
- Morria Announces Safety Results of Phase I Antiallergic Drug
- Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
- Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
- CDC Reorganizes Health and Safety Office
- Safety Leadership
- FAA Announces Decision on Child Safety Seats
 |
 |
User Comments (0)
RSS Feeds